Anton S. Vorobyov

Anton S. Vorobyov

Auto-generated profile, based on publicly available information

Anton S. Vorobyov

Budgetary Institution of Higher Education of Khanty-Mansi Autonomous Okrug – Ugra “Surgut State University”; Research Institute of Internal and Preventive Medicine – Branch of the Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences; Budgetary Institution of the Khanty-Mansiysk Autonomous Okrug – Yugra District Cardiology Dispensary “Center for Diagnostics and Cardiovascular Surgery

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2023 in Russian Cardiology Bulletin
Verified
Journal Article
Closed access
Uliana V ChubykinaUliana V Chubykina
Uliana V Chubykina
Marat EzhovMarat Ezhov
Marat Ezhov
TRT.A. Rozhkova
T.A. Rozhkova
BTB.M. Tamaeva
B.M. Tamaeva
ASA.A. Sokolov
A.A. Sokolov
SBS.E. Bednova
S.E. Bednova
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить комплаентность пациентов с гетерозиготной семейной гиперхолестеринемией (геСГХС) в течение 5-летнего периода работы регистра РЕНЕССАНС (Регистр пациентов с СГХС и пациентов очень высокого сЕрдечно-Сосудистого риска с недоСтАточной эффективНоСтью, проводимой гиполипидемической терапии). МАТЕРИАЛ И МЕТОДЫ РЕНЕССАНС является открытым, национальным, наблюдательным исследованием и включает больных с СГХС. Проводилась оценка факторов риска атеросклероза, анамнеза сердечно-сосудистых заболеваний (ССЗ), интенсивности гиполипидемической терапии (ГЛТ). Каждому пациенту определены уровни общего холестерина, триглицеридов, холестерина липопротеидов высокой плотности в сыворотке крови. Содержание холестерина липопротеидов низкой плотности (ХС ЛНП) рассчитывали по формуле Фридвальда. РЕЗУЛЬТАТЫ В исследование включено 2317 пациентов с геСГХС, из которых 58% — женщин. При включении в регистр 59% больных относились к категории высокого сердечно-сосудистого риска. Динамический визит проведен у 47% пациентов, период наблюдения составил 24 [11; 42] мес. Больные с динамическим визитом чаще имели определенный диагноз геСГХС и отягощенный наследственный анамнез по ССЗ, были моложе и им в более раннем возрасте диагностировали СГХС (p<0,05). У пациентов без динамического визита были распространены модифицируемые факторы риска (p<0,001). Среди пациентов высокого сердечно-сосудистого риска 54% больных получали ГЛТ, очень высокого — 86%. За время наблюдения в регистре доля принимающих ГЛТ пациентов увеличилась с 59 до 78%, в том числе статинами в режиме высокой интенсивности с 36 до 54%, в комбинации с эзетимибом — с 15 до 34%, ингибиторами PCSK9 — с 4 до 14% (p<0,001 для всех). Целевого уровня ХС ЛНП достигли 13% пациентов. Данные симуляционного анализа продемонстрировали, что для адекватного контроля уровня ХС ЛНП, не менее 92,5% больных с геСГХС в регистре должны получать трехкомпонентную ГЛТ со статинами, эзетимибом и ингибиторами PCSK9. ЗАКЛЮЧЕНИЕ 5-летнее наблюдение за участниками регистра РЕНЕССАНС демонстрирует увеличение использования многокомпонентных схем лечения, но недостаточное для адекватного контроля ХС ЛНП.

5 April 2024 in Siberian Journal of Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
VKV. I. Kinash
V. I. Kinash
Vasily KashtalapVasily Kashtalap
Vasily Kashtalap
DFDmitriy Alekseevich Fedorov
Dmitriy Alekseevich Fedorov
AVA. S. Vorobiev
A. S. Vorobiev
IUI. A. Urvantseva
I. A. Urvantseva
LKL. V. Kovalenko
L. V. Kovalenko
Aim: To study the annual outcomes of patients with a confirmed diagnosis of myocardial infarction (MI), depending on its type.Material and Methods. Of the 1,325 hospitalized patients, 1,293 (97.5%) were diagnosed with acute coronary syndrome; the rest had extra-cardiac causes of chest pain. Follow-up included examinations of patients in the hospital and interviewing by phone or email in 12 months after discharge. All patients with MI were tested for the presence of personality type D. After 12 months of follow-up, the total number of patients diagnosed with MI was 255 (92.1%) patients [180 (70.5%) patients with MI1, 75 (29.5%) patients with MI2].Results. After 12 months of follow-up, in the general group of patients complications developed in 53 (20.7%) patients (27 (15.0%) patients in the IM1 group and 26 (34.6%) patients in the IM2 group). Overall mortality and the frequency of repeat- ed hospitalizations for heart failure were higher in MI2 compared to MI1 [8 (10.6%) vs. 2 (1.1%) (p = 0.001) and 9 (12.0%) vs. 8 (4.4%) (p = 0.03), respectively]. The main predictors of adverse events in patients with MI2 were: obesity, p = 0.005; diabetes mellitus, p = 0.006; two-vessel lesion, p = 0.001; three-vessel lesion, р = 0.001; low adherence to drug therapy (< 6 points) on the Morisky-Green scale, p = 0.007; personality type D, p = 0.040. In patients with MI1, the main predictors of adverse events were: obesity, p = 0.019; male, p = 0.009. There were no statistically significant differences in both groups in the frequency of mortality from MI, the development of recurrent MI, as well as complications such as subacute/late stent thrombosis and restenosis in the stent.Conclusion. In patients with MI2, compared with MI1, after 12 months of follow-up the indicators of total mortality (10.6% vs. 1.1%) and repeated hospitalizations due to decompensation of heart failure (12% vs. 4.4%) are higher.

20 July 2023 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
AVA. S. Vorobyov
A. S. Vorobyov
GLGalina Lifshits
Galina Lifshits
EZE. M. Zelenskaya
E. M. Zelenskaya
KBK. Yu. Batueva
K. Yu. Batueva
LKL. V. Kovalenko
L. V. Kovalenko
KNKonstantin Nikolaev
Konstantin Nikolaev
Aim. To determine the associations of allelic variants of the CYP2C19 gene with coronary atherosclerosis and ischemic events in patients with myocardial infarction (MI) living in the Khanty-Mansi Autonomous Okrug — Yugra.Material and methods. This prospective observational study included 203 patients with acute MI who underwent percutaneous coronary intervention. Patients also underwent genetic testing using real-time polymerase chain reaction to determine allelic variants of the CYP2C19 gene. Using biostatistical analysis methods, associations were established between the genotypes of patients with MI, their clinical characteristics and major ischemic events over 7-year follow-up.Results. Significant associations were identified between allelic variants of CYP2C19*2 (*1/*2 and *2/*2) and smoking, right ventricular volume and glomerular filtration rate (GFR). The presence of the allelic variant CYP2C19*3 (*3/*3) was associated with GFR ³90 ml/min/1,73 m2 and impaired glucose tolerance. A significant association was established between the CYP2C19*17 alleles (*1/*17, *17/*17) with coronary atherosclerosis, smoking, levels of troponin T, aspartate aminotransferase, total cholesterol, left ventricular posterior wall thickness, and a history of myocardial infarction. Data from multivariate analysis showed a clear association of allelic variants of CYP2C19*2 (*1/*2 and *2/*2) with the composite endpoint of 7-year follow-up (death, recurrent myocardial infarction, stent/bypass thrombosis, myocardial revascularization). A significant influence of CYP2C19*17 genotypes (*1/*17 and *17/*17) on myocardial revascularization in patients in the post-infarction period was also determined.Conclusion. CYP2C19*2 genotypes (*1/*2 and *2/*2) in MI patients living in Khanty-Mansi Autonomous Okrug — Yugra are clearly associated with ischemic events during a 7-year follow-up. CYP2C19*17 genotypes (*1/*17 and *17/*17) are clearly associated with coronary atherosclerosis and myocardial revascularization in the long-term post-infarction period.

15 December 2023 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
VKV. I. Kinash
V. I. Kinash
Vasily KashtalapVasily Kashtalap
Vasily Kashtalap
AVA. S. Vorobiev
A. S. Vorobiev
IUI. A. Urvantseva
I. A. Urvantseva
LKL. V. Kovalenko
L. V. Kovalenko
Aim. To study the features of psycho-emotional status and its clinical and prognostic significance in patients with type 1 and 2 myocardial infarction (MI).Material and methods. Of the 1293 patients hospitalized at the District Cardiology Dispensary "Center for Diagnostics and Cardiovascular Surgery" with a diagnosis of acute coronary syndrome, 277 (21,4%) patients with confirmed MI were consecutively included in the observational study. There were 194 (15,0%) patients with type 1 MI (MI1) and 83 (6,4%) with type 2 MI (MI2). MI types were determined based on the IV Universal Definition of Myocardial Infarction (UDMI). During the hospital period, type D personality was identified using the Russian version of the Type D scale-14 (DS-14), while the presence and severity of anxiety and depression was assessed using the Hospital Anxiety and Depression Scale (HADS). Follow-up was conducted through outpatient visits, telephone or email interviews for 12 months after discharge. Patients' adherence to drug therapy was assessed using 8-item Morisky Medication Adherence Scale, and quality of life (QoL) using Short Form Medical Outcomes Study (SF-36) questionnaire.Results. During the hospital period, in the group of patients with MI2, patients with type D personality were more often identified compared with MI1 (30 (36,1%) vs 55 (28,3%), p<0,05). Patients with MI2 had a significantly higher subclinical level of anxiety (34 (41,0%) vs 43 (22,2%), p=0,002), expressed level of anxiety (10 (12,1%) vs 12 (6,2%), p=0,011), as well as a significant level of depression (13 (15,7%) vs 14 (7,2%), p=0,03). At the same time, in patients with type D, regardless of MI type, subclinical levels of anxiety and depression were significantly expressed (63 (74,1%) vs 14 (7,3%) (p<0,001) and 58 (68,2%) vs 25 (13,0%) (p<0,001)). There were no significant differences in inhospital complications between the MI1 and MI2 groups depending on type D personality. After 12-month follow-up, patients with the distressed personality type had higher rate of all-cause death (5 (7,2%) vs 5 (1,6%), p<0,05 without type D), rehospitalization for decompensated heart failure (8 (11,5%) vs 9 (4,8%), p=0,04). Patients with type D were less adherent to drug therapy compared to patients without type D (30 (43,4%) vs 9 (4,8%) p=0,001, respectively), and they had lower QoL scores.Conclusion. Type D personality, the presence of anxiety and depression, high all-cause mortality and rehospitalization rate of decompensated heart failure were more often observed in MI2 compared to MI1, as well as in patients with type D, regardless of MI type. Low adherence to drug therapy and poor quality of life, regardless of MI type, were also associated with the type D personality.

18 March 2022 in Complex Issues of Cardiovascular Diseases
Verified
Journal Article
Open access
PDF file
VKV. I. Kinash
V. I. Kinash
АВА. С. Воробьев
А. С. Воробьев
IUI. A. Urvantseva
I. A. Urvantseva
LKL. V. Kovalenko
L. V. Kovalenko
Vasily KashtalapVasily Kashtalap
Vasily Kashtalap
Highlights. The article presents relevant literary data on the epidemiology, main causes, approaches to the diagnostics and treatment of type 2 myocardial infarction patients. The authors emphasize an unfavorable prognosis in these patients due to comorbidity that leads to development of myocardial infarction. They highlight the need to improve and unify approaches to identifying this phenomenon, as well as the necessity to conduct observational and randomized studies to evaluate approaches to the treatment of type 2 myocardial infarction patients.Abstract. The article summarizes the available data from clinical trials and current guidelines, approaches to the definition and type 2 myocardial infarction (MI) differential diagnosis in clinical practice. The attention is focused on the fundamental difference between type 1 and type 2 MI and the need to consider the comorbidities for the identification of etiological factors type 2 MI development. The lack of evidencebased medical data regarding the prognosis and effective treatment of patients with type 2 MI is emphasized. Nevertheless, such patients are characterized with high rates of overall and cardiovascular mortality in hospital and long-term disease course, as well as a high rate of readmission. Thus, there is the need for multicenter observational studies of type 2 MI patients and the development of algorithms for treatment and rehabilitation of this category of patients.

19 November 2021 in Russian Sklifosovsky Journal "Emergency Medical Care"
Verified
Journal Article
Open access
PDF file
IAI. D. Astrakhantseva
I. D. Astrakhantseva
AVA. S. Vorobyov
A. S. Vorobyov
KNK. Yu. Nikolayev
K. Yu. Nikolayev
IUI. A. Urvantseva
I. A. Urvantseva
Aim. To evaluate the efficiency of cardioprotective therapy using intravenous metoprolol in combination with a high dose of atorvastatin in the prevention of myocardial remodeling (MR) and heart failure (HF) in patients with acute ST-segment elevation myocardial infarction (STEMI).Material AND methods. A prospective study included 100 STEMI patients who underwent primary percutaneous intervention (PCI). Depending on the regimens of drug cardioprotection, three groups of patients were formed: the first (2014–2015) — 34 patients who received 80 mg atorvastatin as a part of the basic therapy on the first day of STEMI, then 20–40 mg/day for 30 days. The second group (2017–2018) — 34 patients who received atorvastatin 80 mg/day for a month from the onset of STEMI. The third group (2018–2019) — 32 patients who received intravenous metoprolol tartrate (5–15 mg) and atorvastatin 80 mg/day before PCI for a month from the onset of STEMI. On days 1 and 2 of STEMI and one month later, patients were assessed for serum levels of cardiac biomarkers; on the 1st, 7th days and one month later, echocardiographic studies (EchoCG) were performed. At the end of the observation, clinical and imaging outcomes (MR and HF) were assessed, which were compared with the dynamics of biomarkers between the groups of patients.Results. The combined use of atorvastatin 80 mg/day for a month from the onset of STEMI and a single intravenous injection of metoprolol tartrate (5–15 mg) in the acute phase of STEMI before PCI showed the most significant effects in the prevention of the development of structural and functional myocardial disorders and clinically severe heart failure, and also caused the minimal serum activity of cardiomarkers in the third group of patients in comparison with the first and second groups of patients without this drug combination. Also, correlations between biomarkers and echocardiography indicators were established in the third group of patients who received cardioprotective therapy.Conclusion. The combined use of high-dose atorvastatin for a month with a single intravenous injection of metoprolol tartrate in acute STEMI before PCI prevents the formation of MR and clinically significant HF in the post-infarction period. Comprehensive dynamic assessment of cardiac biomarkers and echocardiography parameters within a month after post-STEMI is a highly informative tools for monitoring the efficiency of cardioprotective therapy.